News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Kathleen Moore, MD

Articles by Kathleen Moore, MD

Kathleen Moore, MD, director of the Oklahoma TSET Phase I Program and an associate professor of the Section of Gynecologic Oncology at The University of Oklahoma College of Medicine

Kathleen Moore, MD, on the Key Takeaways of 3 Clinical Trials Examining Niraparib in BRCA-Mutant Ovarian Cancer

ByKathleen Moore, MD

June 27th 2021

Kathleen Moore, MD, discusses findings compiled from 3 clinical trials of niraparib in patients with ovarian cancer.

Latest Updated Articles

Kathleen Moore, MD, on the Key Takeaways of 3 Clinical Trials Examining Niraparib in BRCA-Mutant Ovarian Cancer
June 27th 2021

Trending on CancerNetwork

FDA Approves Atezolizumab in MIBC Post-Cystectomy with ctDNA MRD

Investigators Initiate Dosing in Phase 1b/2 Trial of SNB-101 in ES-SCLC

107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)

Perioperative Durvalumab Plus Enfortumab Vedotin Improves Survival in MIBC

108 Long-Term Safety and Efficacy of First-Line Next Generation CDK4-Selective Inhibitor Atirmociclib + Letrozole for the Treatment of Patients With HR+/HER2− Metastatic Breast Cancer